Synthetic DNA producer DNA Script and personalised health plan provider Transcarent each closed $200m corporate-backed series C rounds.
Funding:
France-based synthetic DNA producer DNA Script has completed a $200m series C round featuring pharmaceutical firm Merck Group, genomics technology provider Illumina, laboratory equipment maker Agilent, life sciences real estate investment trust Alexandria Real Estate Equities and conglomerate Danaher. The latest tranche included Healthcor Management, EureKare, Irving Investors and accounts and funds advised by T Rowe Price and Baillie Gifford. The $165m first tranche in October 2021 was also backed by investment and financial services group Fidelity,…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
